Plasma homocysteine in obstructive sleep apnoea

Anna Svatikova, Robert Wolk, Mark J. Magera, Abu S. Shamsuzzaman, Bradley G. Phillips, Virend Somers

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Aims Whether increased homocysteine is one mechanism linking obstructive sleep apnoea (OSA) to cardiovascular abnormalities is unclear. We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP). Methods and Results For study A, homocysteine was measured in 22 OSA patients and 20 controls first before sleep, then after 5 h of untreated OSA, and then in the morning after CPAP treatment. Homocysteine was similar in the OSA and control subjects at all three time points, and declined overnight in both groups (P=0.0017, P=0.036, respectively). To further assess this diurnal variation, we studied plasma homocysteine under a full-night protocol in 10 OSA patients and 12 controls (study B). Homocysteine was measured before sleep, in the morning after sleep, and at noon. Results in both OSA and control groups showed an overnight decline in homocysteine which was reversed by noon (repeated measures ANOVA: OSA, P=0.04; controls, P=0.02). Study C showed that disturbed sleep did not affect homocysteine levels in normal subjects. Conclusion There is a significant diurnal variation in plasma homocysteine, so that homocysteine is lower in the morning after waking. Neither OSA nor disturbed sleep elicit acute or chronic changes in homocysteine.

Original languageEnglish (US)
Pages (from-to)1325-1329
Number of pages5
JournalEuropean Heart Journal
Volume25
Issue number15
DOIs
StatePublished - Aug 2004

Fingerprint

Homocysteine
Obstructive Sleep Apnea
Sleep
Continuous Positive Airway Pressure
Cardiovascular Abnormalities
Analysis of Variance
Control Groups

Keywords

  • CPAP
  • Homocysteine
  • Sleep apnoea

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Svatikova, A., Wolk, R., Magera, M. J., Shamsuzzaman, A. S., Phillips, B. G., & Somers, V. (2004). Plasma homocysteine in obstructive sleep apnoea. European Heart Journal, 25(15), 1325-1329. https://doi.org/10.1016/j.ehj.2004.05.018

Plasma homocysteine in obstructive sleep apnoea. / Svatikova, Anna; Wolk, Robert; Magera, Mark J.; Shamsuzzaman, Abu S.; Phillips, Bradley G.; Somers, Virend.

In: European Heart Journal, Vol. 25, No. 15, 08.2004, p. 1325-1329.

Research output: Contribution to journalArticle

Svatikova, A, Wolk, R, Magera, MJ, Shamsuzzaman, AS, Phillips, BG & Somers, V 2004, 'Plasma homocysteine in obstructive sleep apnoea', European Heart Journal, vol. 25, no. 15, pp. 1325-1329. https://doi.org/10.1016/j.ehj.2004.05.018
Svatikova A, Wolk R, Magera MJ, Shamsuzzaman AS, Phillips BG, Somers V. Plasma homocysteine in obstructive sleep apnoea. European Heart Journal. 2004 Aug;25(15):1325-1329. https://doi.org/10.1016/j.ehj.2004.05.018
Svatikova, Anna ; Wolk, Robert ; Magera, Mark J. ; Shamsuzzaman, Abu S. ; Phillips, Bradley G. ; Somers, Virend. / Plasma homocysteine in obstructive sleep apnoea. In: European Heart Journal. 2004 ; Vol. 25, No. 15. pp. 1325-1329.
@article{df70ce613f72494e894e201aa1495a6c,
title = "Plasma homocysteine in obstructive sleep apnoea",
abstract = "Aims Whether increased homocysteine is one mechanism linking obstructive sleep apnoea (OSA) to cardiovascular abnormalities is unclear. We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP). Methods and Results For study A, homocysteine was measured in 22 OSA patients and 20 controls first before sleep, then after 5 h of untreated OSA, and then in the morning after CPAP treatment. Homocysteine was similar in the OSA and control subjects at all three time points, and declined overnight in both groups (P=0.0017, P=0.036, respectively). To further assess this diurnal variation, we studied plasma homocysteine under a full-night protocol in 10 OSA patients and 12 controls (study B). Homocysteine was measured before sleep, in the morning after sleep, and at noon. Results in both OSA and control groups showed an overnight decline in homocysteine which was reversed by noon (repeated measures ANOVA: OSA, P=0.04; controls, P=0.02). Study C showed that disturbed sleep did not affect homocysteine levels in normal subjects. Conclusion There is a significant diurnal variation in plasma homocysteine, so that homocysteine is lower in the morning after waking. Neither OSA nor disturbed sleep elicit acute or chronic changes in homocysteine.",
keywords = "CPAP, Homocysteine, Sleep apnoea",
author = "Anna Svatikova and Robert Wolk and Magera, {Mark J.} and Shamsuzzaman, {Abu S.} and Phillips, {Bradley G.} and Virend Somers",
year = "2004",
month = "8",
doi = "10.1016/j.ehj.2004.05.018",
language = "English (US)",
volume = "25",
pages = "1325--1329",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Plasma homocysteine in obstructive sleep apnoea

AU - Svatikova, Anna

AU - Wolk, Robert

AU - Magera, Mark J.

AU - Shamsuzzaman, Abu S.

AU - Phillips, Bradley G.

AU - Somers, Virend

PY - 2004/8

Y1 - 2004/8

N2 - Aims Whether increased homocysteine is one mechanism linking obstructive sleep apnoea (OSA) to cardiovascular abnormalities is unclear. We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP). Methods and Results For study A, homocysteine was measured in 22 OSA patients and 20 controls first before sleep, then after 5 h of untreated OSA, and then in the morning after CPAP treatment. Homocysteine was similar in the OSA and control subjects at all three time points, and declined overnight in both groups (P=0.0017, P=0.036, respectively). To further assess this diurnal variation, we studied plasma homocysteine under a full-night protocol in 10 OSA patients and 12 controls (study B). Homocysteine was measured before sleep, in the morning after sleep, and at noon. Results in both OSA and control groups showed an overnight decline in homocysteine which was reversed by noon (repeated measures ANOVA: OSA, P=0.04; controls, P=0.02). Study C showed that disturbed sleep did not affect homocysteine levels in normal subjects. Conclusion There is a significant diurnal variation in plasma homocysteine, so that homocysteine is lower in the morning after waking. Neither OSA nor disturbed sleep elicit acute or chronic changes in homocysteine.

AB - Aims Whether increased homocysteine is one mechanism linking obstructive sleep apnoea (OSA) to cardiovascular abnormalities is unclear. We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP). Methods and Results For study A, homocysteine was measured in 22 OSA patients and 20 controls first before sleep, then after 5 h of untreated OSA, and then in the morning after CPAP treatment. Homocysteine was similar in the OSA and control subjects at all three time points, and declined overnight in both groups (P=0.0017, P=0.036, respectively). To further assess this diurnal variation, we studied plasma homocysteine under a full-night protocol in 10 OSA patients and 12 controls (study B). Homocysteine was measured before sleep, in the morning after sleep, and at noon. Results in both OSA and control groups showed an overnight decline in homocysteine which was reversed by noon (repeated measures ANOVA: OSA, P=0.04; controls, P=0.02). Study C showed that disturbed sleep did not affect homocysteine levels in normal subjects. Conclusion There is a significant diurnal variation in plasma homocysteine, so that homocysteine is lower in the morning after waking. Neither OSA nor disturbed sleep elicit acute or chronic changes in homocysteine.

KW - CPAP

KW - Homocysteine

KW - Sleep apnoea

UR - http://www.scopus.com/inward/record.url?scp=3242890759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242890759&partnerID=8YFLogxK

U2 - 10.1016/j.ehj.2004.05.018

DO - 10.1016/j.ehj.2004.05.018

M3 - Article

C2 - 15288160

AN - SCOPUS:3242890759

VL - 25

SP - 1325

EP - 1329

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 15

ER -